Tg Therapeutics (TGTX) 13.13 $TGTX
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
'Mad Money' Lightning Round: Buy, Buy, Buy GlaxoSmithKline and Box
at The Street - Fri Feb 06, 5:00AM CST
Cramer likes JetBlue, prefers EOG Resources to Whiting Petroleum and is avoiding America Movil.
BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), AMX: 21.97 (+0.27), BOX: 20.18 (+0.01), GMCR: 118.53 (+0.56), TGTX: 13.13 (-0.19), JBLU: 16.83 (+0.09), GSK: 47.94 (+1.99), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), EOG: 96.92 (+2.12), IRBT: 31.16 (+0.18)
Pharmaceuticals Remain In The Spotlight - Cramer's Lightning Round (2/5/15)
SA Editor Michael Hopkins - at Seeking Alpha - Fri Feb 06, 1:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday February 5. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ) : "I liked what I heard. I thought it sounded like a good company. I liked Weiss'...
BERY: 34.98 (+0.03), AMX: 21.97 (+0.27), WLL: 38.53 (+2.41), QRVO: 70.03 (+3.83), BOX: 20.18 (+0.01), GMCR: 118.53 (+0.56), TGTX: 13.13 (-0.19), JBLU: 16.83 (+0.09), GSK: 47.94 (+1.99), IRBT: 31.16 (+0.18)
Jim Cramer's 'Mad Money' Recap: Cheap Stocks Aren't Bad Stocks
at The Street - Thu Feb 05, 7:38PM CST
Only in the stock market are lower prices seen as a bad thing, Cramer says.
MMM: 165.94 (+0.03), AMX: 21.97 (+0.27), HON: 104.38 (+0.88), NKE: 92.04 (+0.04), GMCR: 118.53 (+0.56), WMT: 85.81 (-0.08), JBLU: 16.83 (+0.09), LNKD: 269.00 (+1.83), EOG: 96.92 (+2.12), TWTR: 48.50 (+0.55), IRBT: 31.16 (+0.18), CSCO: 29.43 (-0.03), WFM: 56.15 (-0.15), BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), ETN: 72.55 (+0.90), BOX: 20.18 (+0.01), AGCO: 49.78 (+0.97), TGTX: 13.13 (-0.19), GSK: 47.94 (+1.99), IDTI: 20.56 (-0.38), HAIN: 59.48 (+0.45), UA: 73.76 (-0.19), AA: 15.81 (+0.16), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), GM: 37.62 (-0.40), DOW: 49.44 (+0.29)
TG Therapeutics, Inc. to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the 17 Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City. The presentation is scheduled to take place on Monday February 9, 2015 at 2:30pm ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 13.13 (-0.19)
Netflix's Cult Surprise - Cramer's Mad Money (1/21/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Jan 22, 6:25AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 21, 2015 Wednesday's rally will likely be ascribed by many to the ECB's initiative of kickstarting Europe's economy on Thursday. Others will point to...
AMZN: 381.83 (+4.66), TSLA: 203.77 (+0.89), GPRO: 45.27 (-0.02), GOLD: 78.29 (-0.31), UNH: 109.44 (-0.40), TGTX: 13.13 (-0.19), LEA: 108.70 (-0.73), TWX: 83.87 (+0.56), NFLX: 466.10 (+9.37), PM: 82.87 (-0.82), ETP: 60.17 (+0.96), NTRS: 70.08 (-0.51), EBAY: 56.47 (+1.73), IBM: 160.40 (+1.88), USB: 45.07 (-0.05), TWC: 149.74 (+2.21), FOLD: 8.36 (-0.11)
Jim Cramer's Top Stock Picks: NFLX FOLD TGTX
at The Street - Thu Jan 22, 5:00AM CST
Cramer said Netflix can thank binge buying for its share surge while Amicus Therapeutics and TG Therapeutics are biotechs with plenty of potential.
NFLX: 466.10 (+9.37), TGTX: 13.13 (-0.19), FOLD: 8.36 (-0.11)
TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 15, 7:59AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) announced that Michael S. Weiss, the Company's Executive Chairman and Interim CEO, will present an update on the Company's development programs for TG-1101, the Company's novel anti-CD20 monoclonal antibody, and TGR-1202, the Company's novel PI3K delta inhibitor, as well as an overview of TG Therapeutics' corporate goals for 2015. The presentation will occur today, Thursday January 15, at 8:30 am PT, during the 33 Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA.
JPM: 59.67 (+0.10), TGTX: 13.13 (-0.19)
InsiderInsights.com Daily Round Up 1/7/15: RM, OPK, NHF, MLNK
InsiderInsights - at Seeking Alpha - Thu Jan 08, 3:26PM CST
CCO: 9.46 (+0.07), VVUS: 2.68 (+0.13), NU: 51.02 (-1.28), TGTX: 13.13 (-0.19), MLNK: 3.78 (+0.04), RM: 15.88 (+0.96), SRE: 105.56 (-1.11), SHLD: 35.70 (+2.32), GOOG: 549.01 (+6.08), LQ: 21.59 (unch), PPT: 5.23 (+0.01), CTRE: 13.46 (+0.26), BH: 416.41 (-1.55), PLUS: 80.17 (-0.21), OPK: 13.80 (-0.28), JAZZ: 169.69 (+6.89), NHF: 11.69 (+0.08), TWTR: 48.50 (+0.55), CRM: 62.85 (+1.59)
TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Interim Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA. The presentation is scheduled to take place on Thursday, January 15, 2015 at 8:30am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
JPM: 59.67 (+0.10), TGTX: 13.13 (-0.19)
Cramer's Mad Money - Best Biotechs Of 2014 (1/6/15)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Jan 07, 4:38AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday January 6. Best Biotechs of 2014: Isis Pharmaceuticals (NASDAQ: ISIS ), BioMarin (NASDAQ: BMRN ), OvaScience (NASDAQ: OVAS ), Agios (NASDAQ: AGIO ),...
BLUE: 90.70 (+0.93), GE: 25.15 (+0.26), BMRN: 100.76 (+1.98), OVAS: 44.32 (+0.87), XOM: 93.37 (+1.00), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), GLUU: 5.12 (+0.14), LUV: 43.30 (-0.20), T: 34.66 (+0.05), TTWO: 28.40 (+0.96), GT: 25.91 (-0.30), SAVE: 79.32 (-0.80), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), IBM: 160.40 (+1.88), AAL: 48.39 (+0.51), MCD: 95.65 (+0.56), RCPT: 115.83 (-0.66), AGI: 5.78 (+0.03), TWTR: 48.50 (+0.55), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
Commit To Buy TG Therapeutics At $15, Earn 31.1% Annualized Using Options
at The Street - Mon Dec 29, 10:41AM CST
Investors considering a purchase of TG Therapeutics Inc shares, but cautious about paying the going market price of $16.07/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
TGTX: 13.13 (-0.19)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
GlobeNewswire - Wed Dec 17, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the appointment of Kenneth Hoberman to the Company's Board of Directors. Mr. Hoberman is currently the Chief Operating Officer of Stemline Therapeutics, Inc. (Nasdaq:STML), a publicly-traded biotechnology company and was formerly the VP, Corporate and Business Development of Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a publicly-traded biotechnology company.
TGTX: 13.13 (-0.19), STML: 14.07 (-0.10), KERX: 11.63 (-0.60)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 90.70 (+0.93), BMRN: 100.76 (+1.98), TGTX: 13.13 (-0.19), BMY: 60.04 (+0.56), MACK: 10.22 (+0.40), FMI: 48.88 (+0.17), RNA: 18.65 (unch), GWPH: 78.09 (+1.70), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), ICPT: 209.12 (+7.12), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), NVS: 102.20 (-0.17)
TG Therapeutics (TGTX) Is Weak On High Volume Today
at The Street - Mon Dec 15, 9:02AM CST
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a weak on high relative volume candidate
TGTX: 13.13 (-0.19)
TG Therapeutics, Inc. (TGTX) in Focus: Stock Soars 21.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:21AM CST
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise by over 21% on the day.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), TGTX: 13.13 (-0.19), OSUR: 8.13 (+0.06)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 3.84 (unch), PCYC: 163.28 (+0.23), TGTX: 13.13 (-0.19), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), INFI: 15.13 (+0.55), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
'Mad Money' Lightning Round: Buy, Buy, Buy GlaxoSmithKline and Box
at The Street - Fri Feb 06, 5:00AM CST
Cramer likes JetBlue, prefers EOG Resources to Whiting Petroleum and is avoiding America Movil.
BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), AMX: 21.97 (+0.27), BOX: 20.18 (+0.01), GMCR: 118.53 (+0.56), TGTX: 13.13 (-0.19), JBLU: 16.83 (+0.09), GSK: 47.94 (+1.99), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), EOG: 96.92 (+2.12), IRBT: 31.16 (+0.18)
Pharmaceuticals Remain In The Spotlight - Cramer's Lightning Round (2/5/15)
SA Editor Michael Hopkins - at Seeking Alpha - Fri Feb 06, 1:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday February 5. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ) : "I liked what I heard. I thought it sounded like a good company. I liked Weiss'...
BERY: 34.98 (+0.03), AMX: 21.97 (+0.27), WLL: 38.53 (+2.41), QRVO: 70.03 (+3.83), BOX: 20.18 (+0.01), GMCR: 118.53 (+0.56), TGTX: 13.13 (-0.19), JBLU: 16.83 (+0.09), GSK: 47.94 (+1.99), IRBT: 31.16 (+0.18)
Jim Cramer's 'Mad Money' Recap: Cheap Stocks Aren't Bad Stocks
at The Street - Thu Feb 05, 7:38PM CST
Only in the stock market are lower prices seen as a bad thing, Cramer says.
MMM: 165.94 (+0.03), AMX: 21.97 (+0.27), HON: 104.38 (+0.88), NKE: 92.04 (+0.04), GMCR: 118.53 (+0.56), WMT: 85.81 (-0.08), JBLU: 16.83 (+0.09), LNKD: 269.00 (+1.83), EOG: 96.92 (+2.12), TWTR: 48.50 (+0.55), IRBT: 31.16 (+0.18), CSCO: 29.43 (-0.03), WFM: 56.15 (-0.15), BERY: 34.98 (+0.03), CY: 14.76 (+0.01), WLL: 38.53 (+2.41), ETN: 72.55 (+0.90), BOX: 20.18 (+0.01), AGCO: 49.78 (+0.97), TGTX: 13.13 (-0.19), GSK: 47.94 (+1.99), IDTI: 20.56 (-0.38), HAIN: 59.48 (+0.45), UA: 73.76 (-0.19), AA: 15.81 (+0.16), QRVO: 70.03 (+3.83), ISIS: 63.86 (-0.43), GM: 37.62 (-0.40), DOW: 49.44 (+0.29)
TG Therapeutics, Inc. to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the 17 Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City. The presentation is scheduled to take place on Monday February 9, 2015 at 2:30pm ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
TGTX: 13.13 (-0.19)
Netflix's Cult Surprise - Cramer's Mad Money (1/21/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Jan 22, 6:25AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, January 21, 2015 Wednesday's rally will likely be ascribed by many to the ECB's initiative of kickstarting Europe's economy on Thursday. Others will point to...
AMZN: 381.83 (+4.66), TSLA: 203.77 (+0.89), GPRO: 45.27 (-0.02), GOLD: 78.29 (-0.31), UNH: 109.44 (-0.40), TGTX: 13.13 (-0.19), LEA: 108.70 (-0.73), TWX: 83.87 (+0.56), NFLX: 466.10 (+9.37), PM: 82.87 (-0.82), ETP: 60.17 (+0.96), NTRS: 70.08 (-0.51), EBAY: 56.47 (+1.73), IBM: 160.40 (+1.88), USB: 45.07 (-0.05), TWC: 149.74 (+2.21), FOLD: 8.36 (-0.11)
Jim Cramer's Top Stock Picks: NFLX FOLD TGTX
at The Street - Thu Jan 22, 5:00AM CST
Cramer said Netflix can thank binge buying for its share surge while Amicus Therapeutics and TG Therapeutics are biotechs with plenty of potential.
NFLX: 466.10 (+9.37), TGTX: 13.13 (-0.19), FOLD: 8.36 (-0.11)
TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 15, 7:59AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) announced that Michael S. Weiss, the Company's Executive Chairman and Interim CEO, will present an update on the Company's development programs for TG-1101, the Company's novel anti-CD20 monoclonal antibody, and TGR-1202, the Company's novel PI3K delta inhibitor, as well as an overview of TG Therapeutics' corporate goals for 2015. The presentation will occur today, Thursday January 15, at 8:30 am PT, during the 33 Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA.
JPM: 59.67 (+0.10), TGTX: 13.13 (-0.19)
InsiderInsights.com Daily Round Up 1/7/15: RM, OPK, NHF, MLNK
InsiderInsights - at Seeking Alpha - Thu Jan 08, 3:26PM CST
CCO: 9.46 (+0.07), VVUS: 2.68 (+0.13), NU: 51.02 (-1.28), TGTX: 13.13 (-0.19), MLNK: 3.78 (+0.04), RM: 15.88 (+0.96), SRE: 105.56 (-1.11), SHLD: 35.70 (+2.32), GOOG: 549.01 (+6.08), LQ: 21.59 (unch), PPT: 5.23 (+0.01), CTRE: 13.46 (+0.26), BH: 416.41 (-1.55), PLUS: 80.17 (-0.21), OPK: 13.80 (-0.28), JAZZ: 169.69 (+6.89), NHF: 11.69 (+0.08), TWTR: 48.50 (+0.55), CRM: 62.85 (+1.59)
TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company's Interim Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco, CA. The presentation is scheduled to take place on Thursday, January 15, 2015 at 8:30am PT. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.
JPM: 59.67 (+0.10), TGTX: 13.13 (-0.19)
Cramer's Mad Money - Best Biotechs Of 2014 (1/6/15)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Jan 07, 4:38AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday January 6. Best Biotechs of 2014: Isis Pharmaceuticals (NASDAQ: ISIS ), BioMarin (NASDAQ: BMRN ), OvaScience (NASDAQ: OVAS ), Agios (NASDAQ: AGIO ),...
BLUE: 90.70 (+0.93), GE: 25.15 (+0.26), BMRN: 100.76 (+1.98), OVAS: 44.32 (+0.87), XOM: 93.37 (+1.00), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), GLUU: 5.12 (+0.14), LUV: 43.30 (-0.20), T: 34.66 (+0.05), TTWO: 28.40 (+0.96), GT: 25.91 (-0.30), SAVE: 79.32 (-0.80), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), IBM: 160.40 (+1.88), AAL: 48.39 (+0.51), MCD: 95.65 (+0.56), RCPT: 115.83 (-0.66), AGI: 5.78 (+0.03), TWTR: 48.50 (+0.55), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
Commit To Buy TG Therapeutics At $15, Earn 31.1% Annualized Using Options
at The Street - Mon Dec 29, 10:41AM CST
Investors considering a purchase of TG Therapeutics Inc shares, but cautious about paying the going market price of $16.07/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
TGTX: 13.13 (-0.19)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
GlobeNewswire - Wed Dec 17, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the appointment of Kenneth Hoberman to the Company's Board of Directors. Mr. Hoberman is currently the Chief Operating Officer of Stemline Therapeutics, Inc. (Nasdaq:STML), a publicly-traded biotechnology company and was formerly the VP, Corporate and Business Development of Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a publicly-traded biotechnology company.
TGTX: 13.13 (-0.19), STML: 14.07 (-0.10), KERX: 11.63 (-0.60)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 90.70 (+0.93), BMRN: 100.76 (+1.98), TGTX: 13.13 (-0.19), BMY: 60.04 (+0.56), MACK: 10.22 (+0.40), FMI: 48.88 (+0.17), RNA: 18.65 (unch), GWPH: 78.09 (+1.70), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), ICPT: 209.12 (+7.12), THLD: 4.03 (+0.21), CEMP: 27.68 (+1.25), NVS: 102.20 (-0.17)
TG Therapeutics (TGTX) Is Weak On High Volume Today
at The Street - Mon Dec 15, 9:02AM CST
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a weak on high relative volume candidate
TGTX: 13.13 (-0.19)
TG Therapeutics, Inc. (TGTX) in Focus: Stock Soars 21.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:21AM CST
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise by over 21% on the day.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), TGTX: 13.13 (-0.19), OSUR: 8.13 (+0.06)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 3.84 (unch), PCYC: 163.28 (+0.23), TGTX: 13.13 (-0.19), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), INFI: 15.13 (+0.55), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
